Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
80.38
+0.91 (1.15%)
Dec 5, 2025, 4:00 PM EST - Market closed
Monopar Therapeutics Stock Forecast
Stock Price Forecast
According to 12 professional analysts, the 12-month price target for Monopar Therapeutics stock ranges from a low of $40 to a high of $125. The average analyst price target of $97.83 forecasts a 21.71% increase in the stock price over the next year.
Price Target: $97.83 (+21.71%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Monopar Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 7 | 6 | 5 | 5 |
| Buy | 3 | 3 | 4 | 5 | 7 | 7 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 12 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Strong Buy → Buy Downgrades $142 → $123 | Strong Buy → Buy | Downgrades | $142 → $123 | +53.02% | Nov 14, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $100 | Strong Buy | Maintains | $100 | +24.41% | Nov 13, 2025 |
| Leerink Partners | Leerink Partners | Buy Initiates $115 | Buy | Initiates | $115 | +43.07% | Nov 10, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $85 → $100 | Strong Buy | Maintains | $85 → $100 | +24.41% | Nov 9, 2025 |
| Barclays | Barclays | Buy Initiates $125 | Buy | Initiates | $125 | +55.51% | Oct 13, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.70
from -4.11
EPS Next Year
-3.75
from -1.70
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.52 | -1.16 | ||||
| Avg | -1.70 | -3.75 | ||||
| Low | -1.87 | -6.77 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.